Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-26808 Alone or With Tislelizumab in Advanced Solid Tumors
NCT05981703Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2023
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of BGB-26808 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months, Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-26808 at 1 month and 2 more. Started Sep 2023; status: recruiting.
02
Drugs
BGB-26808
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05981703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981703.